Literature DB >> 33015738

Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson's Disease Progression.

Selma Yılmazer1, Esin Candaş2, Gençer Genç3, Merve Alaylıoğlu2, Büşra Şengül2, Ayşegül Gündüz4, Hülya Apaydın4, Güneş Kızıltan4, Sibel Ertan5, Erdinç Dursun2,6, Duygu Gezen-Ak2.   

Abstract

Parkinson's disease (PD) is a chronic neurodegenerative disease that has relatively slow progression with motor symptoms. Leucine-rich repeat kinase 2 (LRRK2) gene mutations and polymorphisms are suggested to be associated with PD. In this study, we aimed to investigate the association between single-nucleotide polymorphisms (SNPs) of the LRRK2 gene, namely, rs11176013, rs10878371, rs11835105, and PD. Genotypes of 132 PD cases and 133 healthy individuals were determined by qRT-PCR. Haplotype analysis was performed. Additionally, LRRK2 mRNA expression levels were determined in 83 PD cases and 55 healthy subjects. The relationship between LRRK2 mRNA levels, the target SNPs, and clinical data was also investigated. Our results indicated that the "GG" genotype and "G" allele of rs11176013 and the "CC" genotype and "C" allele of rs10878371 were more frequent in cases. The "GCG" haplotype was significantly more frequent in cases. LRRK2 mRNA expression levels in patients were significantly lower than those in healthy individuals. The patients with the "CC" genotype for rs10878371 and the "GG" genotype for rs11176013 had decreased LRRK2 mRNA levels. We found that the rs11176013 "GG" genotype and the rs10878371 "CC" genotype were less frequently seen in cases with akinetic rigid or combined akinetic rigid and tremor-dominant initial symptoms. Consequently, our results demonstrate that the rs11176013 and rs10878371 polymorphisms are associated with PD in a Turkish cohort, and moreover, these results suggest that these polymorphisms may affect the expression of the LRRK2 gene and disease progression and thus play a role in the pathogenesis of PD.

Entities:  

Keywords:  LRRK2; Neurodegeneration; Parkinson’s disease; Single-nucleotide polymorphism; mRNA expression

Mesh:

Substances:

Year:  2020        PMID: 33015738     DOI: 10.1007/s12017-020-08619-x

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  44 in total

1.  Vitamin D deficiency might pose a greater risk for ApoEɛ4 non-carrier Alzheimer's disease patients.

Authors:  Erdinç Dursun; Merve Alaylıoğlu; Başar Bilgiç; Haşmet Hanağası; Ebba Lohmann; Irem L Atasoy; Esin Candaş; Ömür Selin Araz; Burak Önal; Hakan Gürvit; Selma Yılmazer; Duygu Gezen-Ak
Journal:  Neurol Sci       Date:  2016-06-29       Impact factor: 3.307

2.  The screening of the 3'UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease.

Authors:  Lucía F Cardo; Eliecer Coto; René Ribacoba; Ignacio F Mata; Germán Moris; Manuel Menéndez; Victoria Alvarez
Journal:  J Hum Genet       Date:  2014-04-24       Impact factor: 3.172

3.  LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.

Authors:  Soraya Bardien; Angelica Marsberg; Rowena Keyser; Debbie Lombard; Suzanne Lesage; Alexis Brice; Jonathan Carr
Journal:  J Neural Transm (Vienna)       Date:  2010-06-11       Impact factor: 3.575

4.  A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-β and preventing the amyloid-β induced alterations by vitamin D in cortical neurons.

Authors:  Erdinç Dursun; Duygu Gezen-Ak; Selma Yilmazer
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Clinical features of LRRK2-associated Parkinson's disease in central Norway.

Authors:  Jan O Aasly; Mathias Toft; Ignacio Fernandez-Mata; Jennifer Kachergus; Mary Hulihan; Linda R White; Matthew Farrer
Journal:  Ann Neurol       Date:  2005-05       Impact factor: 10.422

6.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1.

Authors:  Manabu Funayama; Kazuko Hasegawa; Hisayuki Kowa; Masaaki Saito; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2002-03       Impact factor: 10.422

Review 7.  Stages in the development of Parkinson's disease-related pathology.

Authors:  Heiko Braak; Estifanos Ghebremedhin; Udo Rüb; Hansjürgen Bratzke; Kelly Del Tredici
Journal:  Cell Tissue Res       Date:  2004-08-24       Impact factor: 5.249

8.  [A new look at the corticostriatal-thalamocortical circuit in sporadic Parkinson's disease].

Authors:  H Braak; K Del Tredici
Journal:  Nervenarzt       Date:  2008-12       Impact factor: 1.214

9.  The Association Between Clusterin and APOE Polymorphisms and Late-Onset Alzheimer Disease in a Turkish Cohort.

Authors:  Merve Alaylıoğlu; Duygu Gezen-Ak; Erdinç Dursun; Başar Bilgiç; Haşmet Hanağası; Turan Ertan; Hakan Gürvit; Murat Emre; Engin Eker; Ömer Uysal; Selma Yılmazer
Journal:  J Geriatr Psychiatry Neurol       Date:  2016-04-12       Impact factor: 2.680

10.  Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.

Authors:  Michael J Devine; Alice Kaganovich; Mina Ryten; Adamantios Mamais; Daniah Trabzuni; Claudia Manzoni; Philip McGoldrick; Diane Chan; Allissa Dillman; Julia Zerle; Susannah Horan; Jan-Willem Taanman; John Hardy; Jose-Felix Marti-Masso; Daniel Healy; Daniel Healey; Anthony H Schapira; Benjamin Wolozin; Rina Bandopadhyay; Mark R Cookson; Marcel P van der Brug; Patrick A Lewis
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

View more
  1 in total

1.  iPSC-Derived Microglia as a Model to Study Inflammation in Idiopathic Parkinson's Disease.

Authors:  Katja Badanjak; Patrycja Mulica; Semra Smajic; Sylvie Delcambre; Leon-Charles Tranchevent; Nico Diederich; Thomas Rauen; Jens C Schwamborn; Enrico Glaab; Sally A Cowley; Paul M A Antony; Sandro L Pereira; Carmen Venegas; Anne Grünewald
Journal:  Front Cell Dev Biol       Date:  2021-11-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.